- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma
Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.
vemurafenib (Brand name:
Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
